CHEOF (Cochlear) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHEOF Cochlear Ltd CHEOF
60 GF Score
Price $81.92
GF Value $215.08
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Cochlear FFO per Share?

FFO per Share only applies to REITs.

CHEOF
60GF Score
Cochlear Ltd CHEOF
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Cochlear (CHEOF) Overvalued in 2026?

Based on GuruFocus' analysis, Cochlear stock appears to be undervalued. The current stock price of $81.92 is trading 61.9% below its estimated GF Value™ of $215.08. GuruFocus considers Cochlear to be Significantly Undervalued.

Key valuation signals for CHEOF:

  • FFO per Share:
  • GF Value™: $215.08 vs. price of $81.92 (61.9% below fair value)
  • GF Score™: 60/100 with 2 warning signs

No single metric tells the full story. See the CHEOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cochlear Business Description

Address 1 University Avenue, Macquarie University, Sydney, NSW, AUS, 2109
Cochlear is the leading cochlear implant device manufacturer, with around 60% global market share. Developed markets contribute 80% of group revenue, where cochlear implants are the standard of care for children with severe-to-profound hearing loss. The company also actively targets the growing cohort of seniors in developed markets. Tender-oriented emerging markets contribute the remaining 20% of group revenue. Main products include cochlear implants, bone-anchored hearing aids, and associated sound processors. In fiscal 2025, 49% of revenue came from the Americas, 34% from Europe, the Middle East, and Africa, and 18% from the Asia-Pacific segment.
60GF Score

Get the complete analysis for CHEOF

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$81.92
Price
$215.08
GF Value